Igenica Appoints Mary Haak-Frendscho CEO
This article was originally published in Scrip
Igenica, a biopharmaceutical company discovering and developing cancer antibody therapeutics, has named Dr Mary Haak-Frendscho CEO and a member of the board of directors. Dr Haak-Frendscho, who was previously the founding president and CSO of Takeda San Francisco, succeeds Dr David Goeddel, who remains as Igenica's chair.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.